ERBB2 and triple-negative breast carcinoma: Other studies indicate that triple negative breast cancers and HER2-overexpressing breast cancers that are treated with post-mastectomy RT have increased risks of locoregional recurrence and metastasis, along with significantly reduced overall survival (59–61).